GSK Consumer Healthcare to fight case against tech transfer

New Delhi: GSK Consumer Healthcare said it will contest an attempt by Steer Engineering to block the transfer of technology that quickens the process of making malt beverages to Hindustan Unilever as part of a planned merger.

“We are contesting allegations made by Steer Engineering and shall take all necessary legal steps before the Delhi High Court. As the matter is sub-judice, we are not in a position to share further details,” a GSK Consumer spokesperson said in response to ET’s query.

Unilever’s India unit announced on December 3 that it will merge GSK Consumer with itself in an all-stock deal that will give it access to Horlicks, Boost and Maltova malted drinks.

The merger values GSK Consumer at Rs 31,700 crore.

Following the merger announcement, Steer Engineering moved the Delhi High Court late last week seeking protection for the technology it had provided for the manufacture of malt beverages Horlicks and Boost.

Steer Engineering said the technology was given exclusively to GSK Consumer and it cannot be transferred to Hindustan Unilever since it is “against the original terms of the contract.”

The company said it has a confidentiality contract with GSK Consumer for the technology, which reduces the time taken to make Horlicks to 15 minutes from 18 hours.

  • Related Posts

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    CHENNAI: The Madras High Court on Friday dismissed a petition seeking to quash a First Information Report (FIR) registered against Puducherry-based pharmaceutical entities accused of manufacturing and distributing counterfeit medicines…

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh: Riding on policy reforms that earned it the top rank among large states in NITI Aayog’s Investment Friendliness Index 2026 for Regulatory Ease and Institutional Environment, Chhattisgarh has received…

    Leave a Reply

    Your email address will not be published. Required fields are marked *

    You Missed

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Madras HC Refuses To Quash FIR In Counterfeit Drug Case, Orders CBI To Complete Probe In 12 Weeks

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    Chhattisgarh draws Rs 992.53 Cr worth pharma investment proposals in 18 months

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    FSSAI suspends license of Punjab-based Rehaan Healthcare for breach of norms at manufacturing unit

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Pharma companies in a flux over Trump’s 200% tariff move on generics

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    Noida Raid Uncovers Suspected ₹2.48-Crore Diversion of Life-Saving Medicines; Probe Expands Into Government Supply Chain and Interstate Network

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’

    CDSCO Directs Safety Updates for Ibuprofen and Aceclofenac Over Risk of ‘Fixed Drug Eruption’